Prelude Therapeutics PRT543 Phase 1 Clinical Trial PRMT5 Inhibitor

Phase 1 dose-escalation study of PRT543, a potent selective oral PRMT5 inhibitor, in patients with advanced solid tumors and lymphoma. PRT543 demonstrated robust preclinical antitumor activity in adenoid cystic carcinoma and HRD-positive breast cancer PDX models. Study evaluates safety, tolerability, and efficacy of this novel PRMT5 inhibitor across multiple cancer types.